6505--Mesoblast, Inc. Contract Award effective 02/15/2026-02/14/2031
Veterans Affairs · NAC FEDERAL SUPPLY SCHEDULE (36F797)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation M5Q50A03R8 in this department, oldest first.
- Oct 12, 2023Award NoticePROVENTION BIO INC · $5.0MOpen
- Nov 6, 2023Award NoticeSCPHARMACEUTICALS INC. · $601KOpen
- Apr 11, 2024Award NoticeBristol-Myers Squibb Company · $12.3BOpen
- May 22, 2024Award NoticeZANFEL LABORATORIES, INCOpen
- Jun 26, 2024Award NoticePHATHOM PHARMACEUTICALS, INC. · $250KOpen
- Sep 12, 2024Award NoticeFIRST NATION GROUP LLCOpen
- Dec 6, 2024Award NoticeDAY ONE BIOPHARMACEUTICALS, INCOpen
- May 12, 2025Award NoticeNATIONAL VITAMIN CO., INCOpen
- Jul 11, 2025Award NoticeBRIDGEBIO PHARMA, INC. · $250KOpen
- Jul 28, 2025Award NoticeSOLENO THERAPEUTICS INCOpen
- Aug 13, 2025Award NoticeIONIS PHARMACEUTICALS, INC.Open
- Feb 13, 2026 · this noticeAward NoticeMESOBLAST, INC.
- Apr 27, 2026Award NoticeMESOBLAST, INC.Open
- May 27, 2026Award NoticeNEUROCRINE BIOSCIENCES, INC.Open
- Aug 27, 2026Award NoticeRECKITT BENCKISER LLCOpen
- Sep 25, 2026Award NoticeWILSHIRE PHARMACEUTICALS, INC · $27.2MOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
Who won similar work
76 award notices on SAM.gov in the last 24 months. Matched by: Same office (NAC FEDERAL SUPPLY SCHEDULE (36F797)), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (74): middle half $721K to $173.8M, median $24.4M; range $225K to $8.0B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| VALNEVA USA, INC. | 2 | $4.3M | Sep 29, 2025 |
| ELI LILLY AND COMPANY · $LLY · $34.1B | 1 | $8.0B | Sep 17, 2025 |
| MERCK SHARP & DOHME LLC · $MRK · $60.1B | 1 | $5.8B | May 22, 2025 |
| Takeda Pharmaceuticals America, Inc. | 1 | $5.6B | Aug 7, 2026 |
| BAUSCH HEALTH US LLC · $BHC · $8.8B | 1 | $3.7B | Sep 14, 2026 |
| SUMITOMO PHARMA AMERICA, INC. | 1 | $2.9B | Aug 24, 2026 |
| ALKERMES, INC. · $ALKS · $1.7B | 1 | $1.7B | Jul 10, 2026 |
| UCB, INC | 1 | $1.1B | Sep 9, 2025 |
| IPSEN BIOPHARMACEUTICALS INC | 1 | $760.7M | May 28, 2026 |
| Indivior Inc. | 1 | $748.9M | Apr 27, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $LLY reported $34.1B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is under 0.1% of that. 10-K
- $MRK reported $60.1B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is under 0.1% of that. 10-K
- $BHC reported $8.8B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is 0.3% of that. 10-K
- $ALKS reported $1.7B revenue in FY2025. The median single-winner award in these 74 past awards, $24.4M, is 1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Sep 29, 2026DECIPHERA PHARMACEUTICALS, LLC$183.8M6505--Deciphera Pharmaceuticals LLC (65IB), 36F79726D0211, Effective 09/29/2026 - 09/28/2031No listed company matched (Materiality N/A)
- Sep 24, 202660 DEGREES PHARMACEUTICALS, INC.$475K6505--60 Degrees Pharmaceuticals, Inc. 65IB 36F79726D0212 9/29/2026 TO 9/28/2031Materiality: 78.2% of $SXTP revenue (High) SEC
- Sep 24, 2026CYTOKINETICS, INCORPORATED$500K6505--Cytokinetics, Incorporated Effective: 09/29/2026 - 09/28/2031Materiality: 6.6% of $CYTK revenue (High) SEC
- Sep 23, 2026GENZYME CORPORATION$670.0M6505--Genzyme CorporationNo listed company matched (Materiality N/A)
- Sep 17, 2026LANTHEUS MEDICAL IMAGING, INC.$76.0M6505--65IB: Lantheus Medical Imaging Inc. | 36F79726D0204 | Period of Performance: 09/30/2026 to 09/30/2031No listed company matched (Materiality N/A)
- Sep 17, 2026VIVUS LLC$285.7M6505--Vivus LLC, 65IB, 36F79726D0185, Performance Period: 09/29/2026 - 09/30/2031No listed company matched (Materiality N/A)
- Sep 16, 2026CHIESI USA INC$50.0M6505--Chiesi USA, Inc. 65IB, 36F79726D0203 09/30/2026-09/29/2031No listed company matched (Materiality N/A)
- Sep 14, 2026BAUSCH HEALTH US LLC$3.7BBausch Health US, LLC Award 09/30/2026 - 09/30/2031Materiality: 42.0% of $BHC revenue (High) SEC
- Aug 31, 2026LUNDBECK LLC$76.0M6505--Lundbeck LLC. 65IB 36F79726D0172 09/15/2026 - 09/14/2031No listed company matched (Materiality N/A)
- Aug 24, 2026SUMITOMO PHARMA AMERICA, INC.$2.9B6505--Sumitomo Pharma America, Inc. 09/01/2026 - 08/31/2031No listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (14 filings)
- 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- $140K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 8 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 4 of the past winners are listed companies
- 0 insider buys and 17 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.